Stalled growth, margin squeeze behind recovery narrative

OPM 16.2%, NPM 6.9%, PAT ₹116.4 Cr (matches ₹1.17B)

INR revenue +8.9% YoY, -2.1% QoQ; CC weaker than delivered INR

Wins noted but revenue conversion timing uncertain; no Q1 revenue yet reflected

Qorix loss and forex noted, but 32% PAT YoY decline is material; core margins also under pressure from fixed-price mix shift

No quantified growth rate given; Q2 expected flattish, implying weak H1; timing of H2 inflection unconfirmed

Analyst notes strategic clients down only 1.3% but overall revenue down 2.1% QoQ; Europe hit quantified, offset mechanism unclear

June Investor Day expected EBITDA 20.5–21.2% for FY27. Q1 delivered 17.2%, Europe weakness ~4% impact quantified. Analyst Chandramouli noted macro changed post-Investor Day, forcing revision.

Japan SDV program cancelled last-minute (vs planned completion); Europe SDV to production end as planned. Combined impact front-loaded into H1.

600–700 bps shift from T&M to fixed-price in past 2–3 quarters; management frames as strategic (margin recovery via AI), but Q1 EBITDA shortfall suggests near-term pressure.

Qorix (JV) loss expected to continue 1–2 more quarters per management; non-operational but material to PAT. No change in expectations, but confirmed persistence.

Management says engaging two Chinese OEMs, products gaining traction; no new quantified milestones. Scale waiting for Chinese OEM volume recovery.

CV will grow next quarter; one-time license deal last quarter inflates QoQ comparison. Europe not permanent drop; pipeline strong but timing uncertain for 1–2 quarters.

Medium-term outlook remains good. Product/solution revenues will grow exponentially; we have already seen success. Outcome-based business models will help reach target.

Growth fairly balanced across portfolio, good visibility for upcoming quarters to continue.

Europe impact ~4% for quarter. Impact will show in Q2 at geography level, not company level—offset by US and SIMA growth.

Europe program almost ending (going to production, planned). Japan program cancelled at last minute. Both ending naturally; don't have clear timing for further revenue.

FX impact and acquisition provisions. Margins will improve incrementally, not significantly, until revenues grow. Qorix loss to continue 1–2 quarters. Revenue is major driver.

Engaging two Chinese OEMs; one approaching meaningful engagement. Found traction for products/solutions in China. Scale will happen; Chinese OEM volumes down, but KPIT seen as partner for global growth.

H2 better than H1, Q4 meaningful growth. Major changes in European ecosystem created uncertainty. Impact is in couple of key clients, but growth broad-based. Medium-term strategy intact.

Move to fixed-price is foundational. AI adoption takes time for client buy-in. Solutions and products (Beacon platform) have better margins. Flexibility to drive margins up incrementally over time.

European OEMs under pressure; conversations shifted to cost reduction (30–40% product cost, production cost). Talks initiated, will take time. Broad-based growth across geographies is focus, not European OEM recovery alone.

Hydrogen tech ongoing but meaningful revenue takes time. Exploring drones, humanoids, production floor solutions. Sodium-ion: battery tech takes 2–3 years to pilot, $100M+ investment, then royalty milestones. Not factoring significant growth.

Conversion happening in certain accounts. European wins will convert but phased; they will use more India resources. Two key European accounts showed drop, but other markets offsetting. No issue with earlier wins.

Absolutely yes, doing pretty well. But OEM engagement model will change to best-of-solutions providers, not traditional vendor consolidation.

N-Dream in-vehicle gaming platform is first-of-its-kind in India. Per-vehicle license model. OEMs use partners like KPIT alongside ER&D, just like other OEMs. Tata relationship long-standing.

CV had large one-time license deal last quarter, smaller base this quarter. Japan program ending as planned; Europe program completion in Q2. CV to grow going forward.

H1 soft due to European shock + program ramp-downs. H2 inflection driven by cost-reduction revenue ramp, new OEM wins, and products/solutions.

Fixed-price contracting up 600–700 bps creates near-term pressure. AI, solutions, Beacon to offset. European cost-outs take longer than other regions.

Contingent on products/solutions contributing ~50% of revenue and exponential growth. Near-term margin trajectory (Q2–Q4) unspecified.

Microsoft partnership for Beacon suggests shared infrastructure investment; no capex % of revenue disclosed.

Europe represents >50% of current revenue. Chinese competition in EU, Chinese OEM EV gains, US tariffs, war input costs creating structural profitability crisis for European OEMs. Conversations on cost-reduction initiated but no contracts yet; recovery timing uncertain.

600–700 bps shift from T&M to fixed-price in past 2–3 quarters already visible in Q1 EBITDA 17.2% vs prior guide 20.5–21.2%. Management frames this as strategic (AI offsets margin), but AI adoption timelines unproven; margin recovery dependent on revenue growth and client infrastructure access.

Japan SDV program cancelled at last minute (vs planned completion); Europe SDV program ramping to production. Combined impact ~4–5% of revenue materializing in Q1–Q2. Timing of European impact to Q2 confirms revenue pull-forward risk.

Qorix share of loss impacting PAT materially. Management expects continuation 1–2 more quarters. Loss result of European revenue postponement and JV cash burn. Contingent on European customer revenue recovery.

June Investor Day guidance (EBITDA 20.5–21.2% for FY27) missed in Q1 (17.2%). European macro shock cited as reason for revision, but no updated FY27 guidance offered this call. H2 recovery promised but unquantified; timing uncertain.